Answers are grounded in this paper and cite their sources.
These findings suggest that debrisoquine poor metaboliser status is not primarily responsible for terodiline cardiotoxicity. However, possession of the CYP2C19*2 allele appears to contribute to adverse cardiac reactions to terodiline. The present study demonstrates the feasibility of using spontaneous adverse drug reaction reporting schemes to determine the contribution of genotype for metabolizing enzymes to uncommon adverse drug reactions.
No takes yet. Share an insight, caveat, or question.
Ford et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: